All In Biotech

Drug Trial Radar · NCT04875195

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

66

Actual

Start

Jun 7, 2021

Primary completion

Dec 14, 2023

Study completion Oct 13, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).

Conditions

  • Hodgkin's Lymphoma
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Interventions

  • PembrolizumabBiological

    Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Per Lugano Classification as Assessed by InvestigatorTime frame: Up to approximately 30 months

Locations

27 sites in 11 countries. Site status is shown where the registry gives one.

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site

    Torrance, California

  • Tulane Medical Center ( Site 0110)

    New Orleans, Louisiana

  • Anne Arundel Medical Center-Anne Arundel Oncology and Hematology ( Site 0125)

    Annapolis, Maryland

  • Hospital Erasto Gaertner ( Site 1703)

    Curitiba, Paraná, Brazil

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1701)

    Barretos, São Paulo, Brazil

  • Cross Cancer Institute ( Site 0207)

    Edmonton, Alberta, Canada

  • Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0304)

    Hradec Králové, Czechia

  • Fakultni nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0302)

    Brno, Brno-mesto, Czechia

  • Fakultni nemocnice Kralovske Vinohrady-Interni hematologicka klinika ( Site 0303)

    Prague, Praha 10, Czechia

  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 0401)

    Dijon, Cote-d Or, France

  • Gustave Roussy ( Site 0402)

    Villejuif, Île-de-France Region, France

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0503)

    Naples, Italy

  • Fondazione IRCCS Policlinico San Matteo ( Site 0509)

    Pavia, Lombardy, Italy

  • Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO-EMATOLOGIA I ( Site 0507)

    Palermo, Sicily, Italy

  • Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-Oddzial Hematologii i Transplantacji S

    Poznan, Greater Poland Voivodeship, Poland

  • Pratia MCM Krakow ( Site 0064)

    Krakow, Lesser Poland Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0063)

    Gdansk, Pomeranian Voivodeship, Poland

  • The National Medico-Surgical Center N.I. Pirogov ( Site 0801)

    Moscow, Moscow, Russia

  • Moscow City Clinical Hospital S.P. Botkin ( Site 0803)

    Moscow, Moscow, Russia

  • Almazov National Medical Research Centre ( Site 0807)

    Saint Petersburg, Sankt-Peterburg, Russia

  • Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 0902)

    Centurion, Gauteng, South Africa

  • Wits Clinical Research ( Site 0904)

    Johannesburg, Gauteng, South Africa

  • Groote Schuur Hospital ( Site 0906)

    Cape Town, Western Cape, South Africa

  • Ankara University Department of Hematology, Clinical Research Unit ( Site 1101)

    Ankara, Turkey (Türkiye)

  • Ege University Medicine of Faculty ( Site 1105)

    Bornova, İzmir, Turkey (Türkiye)

  • CNPE Regional Center of Oncology ( Site 1305)

    Kharkiv, Kharkiv Oblast, Ukraine

  • National Cancer Institute ( Site 1303)

    Kyiv, Kyivska Oblast, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.